XML 62 R54.htm IDEA: XBRL DOCUMENT
v3.24.2

License Agreement with Duke - Additional Information (Detail) |  |  |  | 3 Months Ended | 6 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 17, 2023 USD ($) Patients | Feb. 04, 2022 USD ($) | Feb. 23, 2021 USD ($) | May 31, 2024 USD ($) ft² shares | Nov. 30, 2023 USD ($) | May 31, 2023 USD ($) | May 31, 2024 USD ($) ft² shares | May 31, 2023 USD ($) | Feb. 23, 2023 USD ($) | Feb. 28, 2021 USD ($) | Dec. 01, 2020 USD ($)
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  | $ 8,042,811 |  | $ 7,772,690 | $ 15,895,046 | $ 15,597,105 |  |  |
Impairment of assets |  |  |  |  | $ 13,108,064 |  |  |  |  |  |
Duke University [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
License fee payable |  |  |  |  |  |  |  |  | $ 2,000,000 |  | $ 12,000,000
Milestone payments first phase III clinical trial |  | $ 2,000,000 | $ 2,000,000 |  |  |  |  |  |  |  |
Capitalized costs to obtain agreement |  |  |  |  |  |  |  |  |  | $ 15,372,382 |
Present value of license fee |  |  |  | 12,000,000 |  |  | 12,000,000 |  |  |  |
Number of common stock value transferred |  |  |  | $ 3,585,172 |  |  | $ 3,585,172 |  |  |  |
Number of common stock shares transferred | shares |  |  |  | 409,734 |  |  | 409,734 |  |  |  |
Capitalized costs amortization period |  |  |  | 16 years |  |  | 16 years |  |  |  |
Amortization expense |  |  |  | $ 0 |  | 240,194 | $ 0 | 480,387 |  |  |
Duke University [Member] | 5.0% upon Execution of the Agreement [Member] | Fully Diluted Equity Ownership |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |  |  | 5.00% |  |  |  |  |  |  |  |
Duke University [Member] | 2.5% Market Cap [Member] | Fully Diluted Equity Ownership |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |  |  | 2.50% |  |  |  |  |  |  |  |
Duke University [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalties Percentage Portion of Net Sales |  |  | 7.00% |  |  |  |  |  |  |  |
Duke University [Member] | Minimum [Member] | 2.5% Market Cap Triggers with 18 Months [Member] | Fully Diluted Equity Ownership |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Average Closing Market Capital |  |  | $ 300,000,000 |  |  |  |  |  |  |  |
Duke University [Member] | Minimum [Member] | 2.5% Market Cap Triggers with 24 Months [Member] | Fully Diluted Equity Ownership |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Average Closing Market Capital |  |  | $ 500,000,000 |  |  |  |  |  |  |  |
Duke University [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalties Percentage Portion of Net Sales |  |  | 12.50% |  |  |  |  |  |  |  |
Duke University [Member] | Within Fourteen (14) days of February 23, 2021 |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
License fee payable |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Duke University [Member] | Second Anniversary [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Two |  |  | 500,000 |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Three |  |  | 1,000,000 |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Four |  |  | 2,500,000 |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Five |  |  | 5,000,000 |  |  |  |  |  |  |  |
Minimum Annual Royalties Due After Year Five |  |  | $ 5,000,000 |  |  |  |  |  |  |  |
Duke University [Member] | Third Anniversary [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Three |  | 500,000 |  |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Four |  | 1,000,000 |  |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Five |  | 2,500,000 |  |  |  |  |  |  |  |  |
Minimum Annual Royalties Due Year Six |  | 5,000,000 |  |  |  |  |  |  |  |  |
Minimum Annual Royalties Due After Year Six |  | $ 5,000,000 |  |  |  |  |  |  |  |  |
Duke University [Member] | Licensed Product and Licensed Process [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Area of medical condominium building | ft² |  |  |  | 56,000 |  |  | 56,000 |  |  |  |
Royalties Term |  |  |  |  |  |  | 15 years |  |  |  |
Duke University [Member] | Licensed Product and Licensed Process [Member] | 2.5% Upon Cumulative Net Sales [Member] | Fully Diluted Equity Ownership |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |  |  | 2.50% |  |  |  |  |  |  |  |
Revenue |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Duke University [Member] | Licensed Product and Licensed Process [Member] | 2.5% Upon Cumulative Net Sales [Member] | Fully Diluted Equity Ownership |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |  |  | 2.50% |  |  |  |  |  |  |  |
Revenue |  |  | $ 75,000,000 |  |  |  |  |  |  |  |
Second Amendment to the License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment towards funding and completion of study | $ 2,000,000 |  |  |  |  |  |  |  |  |  |
Research Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Additional Consideration Payable | 2,000,000 |  |  |  |  |  |  |  |  |  |
Monthly Instalment payable | 187,407 |  |  |  |  |  |  |  |  |  |
Consideration payable for research | $ 187,400 |  |  |  |  |  |  |  |  |  |
Number of patients in trial's targeted accrual | Patients | 137 |  |  |  |  |  |  |  |  |  |
Emmes Biopharma Services [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
License fee |  |  |  | $ 6,352,291 |  |  | $ 6,352,291 |  |  |  |
Payment due on execution |  |  |  | 100,000 |  |  | 100,000 |  |  |  |
Management fee payable per month |  |  |  | 21,862 |  |  | $ 21,862 |  |  |  |
License fee payment completion term |  |  |  |  |  |  | 53 months |  |  |  |
Cost of trial estimated |  |  |  | 20,000,000 |  |  | $ 20,000,000 |  |  |  |
Emmes Biopharma Services [Member] | Research And Development Expense [Member] |  |  |  |  |  |  |  |  |  |  |
Patent Option And Technology License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |  |
Clinical trial expenses |  |  |  | $ 87,849 |  | $ 0 | $ 181,948 | $ 0 |  |  |

X
- Definition Additional Consideration Payable + References No definition available. + Details
Name: | ccel_AdditionalConsiderationPayable
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Average closing market capital. + References No definition available. + Details
Name: | ccel_AverageClosingMarketCapital
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Clinical trial expenses. + References No definition available. + Details
Name: | ccel_ClinicalTrialExpenses
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Common stock equal full diluted equity ownership outstanding percentage. + References No definition available. + Details
Name: | ccel_CommonStockEqualFullDilutedEquityOwnershipOutstandingPercentage
Namespace Prefix: | ccel_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration payable for research + References No definition available. + Details
Name: | ccel_ConsiderationPayableForResearch
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cost of trial estimated. + References No definition available. + Details
Name: | ccel_CostOfTrialEstimated
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License fee. + References No definition available. + Details
Name: | ccel_LicenseFee
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License fee payable. + References No definition available. + Details
Name: | ccel_LicenseFeePayable
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License fee payment completion term + References No definition available. + Details
Name: | ccel_LicenseFeePaymentCompletionTerm
Namespace Prefix: | ccel_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | ccel_MilestonePayments
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum annual royalties due after year five. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueAfterYearFive
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum annual royalties due after year six. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueAfterYearSix
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum annual royalties due year five. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueYearFive
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum annual royalties due year four. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueYearFour
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum annual royalties due year six. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueYearSix
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum annual royalties due year three. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueYearThree
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum annual royalties due year two. + References No definition available. + Details
Name: | ccel_MinimumAnnualRoyaltiesDueYearTwo
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Monthly Instalments amount payable as consideration for Sponsored Research. + References No definition available. + Details
Name: | ccel_MonthlyInstalmentsPayableAsConsiderationForSponsoredResearch
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of common stock shares transferred. + References No definition available. + Details
Name: | ccel_NumberOfCommonStockSharesTransferred
Namespace Prefix: | ccel_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of common stock value transferred. + References No definition available. + Details
Name: | ccel_NumberOfCommonStockValueTransferred
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of patients in trial's targeted accrual. + References No definition available. + Details
Name: | ccel_NumberOfPatientsInTrialsTargetedAccrual
Namespace Prefix: | ccel_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Patent option and technology license agreement. + References No definition available. + Details
Name: | ccel_PatentOptionAndTechnologyLicenseAgreementLineItems
Namespace Prefix: | ccel_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment due on execution. + References No definition available. + Details
Name: | ccel_PaymentDueOnExecution
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment towards funding and completion of study + References No definition available. + Details
Name: | ccel_PaymentTowardsFundingAndCompletionOfStudy
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Present value of license fee. + References No definition available. + Details
Name: | ccel_PresentValueOfLicenseFee
Namespace Prefix: | ccel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalties percentage portion of net sales. + References No definition available. + Details
Name: | ccel_RoyaltiesPercentagePortionOfNetSales
Namespace Prefix: | ccel_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalty term, + References No definition available. + Details
Name: | ccel_RoyaltiesTerm
Namespace Prefix: | ccel_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Area of a real estate property. + References No definition available. + Details
Name: | us-gaap_AreaOfRealEstateProperty
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:areaItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details
Name: | us-gaap_CapitalizedContractCostAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -SubTopic 40 -Topic 340 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-2 + Details
Name: | us-gaap_CapitalizedContractCostAmortizationPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details
Name: | us-gaap_CapitalizedContractCostNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details
Name: | us-gaap_ImpairmentOfOngoingProject
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of fee payable for management of fund or trust. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details
Name: | us-gaap_ManagementFeePayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ccel_DukeUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=ccel_FivePercentUponExecutionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ccel_FullyDilutedEquityOwnershipMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=ccel_TwoPointFivePercentOfMarketCapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=ccel_TwoPointFivePercentOfMarketCapTriggerOccursEighteenMonthsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=ccel_TwoPointFivePercentOfMarketCapTriggerOccursTwentyFourMonthsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ccel_FourteenDaysOfFebruaryDateTwoThreeYearTwoZeroTwoOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ccel_SecondAnniversaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ccel_ThirdAnniversaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ccel_LicensedProductAndLicensedProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=ccel_TwoPointFivePercentUponCumulativeNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=ccel_TwoPointFivePercentUponCumulativeNetSalesOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ccel_SecondAmendmentToTheLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ccel_ResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ccel_EmmesBiopharmaServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |